Full Text View
Tabular View
No Study Results Posted
Related Studies
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
This study has been completed.
Study NCT00093990   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: October 7, 2004   Last Updated: September 19, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myeloid Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Tipifarnib;Zarnestra; R115777
Additional drug interventions recognized in this trial
Tipifarnib
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services